E-cadherin/ROS1 inhibitor synthetic lethality in breast cancer

The cell adhesion glycoprotein E-cadherin (CDH1) is commonly inactivated in breast tumours. Precision medicine approaches that exploit this characteristic are not available. Using perturbation screens in breast tumour cells with CRISPR-Cas9 engineered CDH1 mutations, we identified synthetic lethalit...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Discov
Hauptverfasser: Bajrami, Ilirjana, Marlow, Rebecca, van de Ven, Marieke, Brough, Rachel, Pemberton, Helen N., Frankum, Jessica, Song, Fei Fei, Rafiq, Rumana, Konde, Asha, Krastev, Dragomir B., Menon, Malini, Campbell, James, Gulati, Aditi, Kumar, Rahul, Pettitt, Stephen J., Gurden, Mark D., Cardenosa, Marta Llorca, Chong, Irene, Gazinska, Patrycja, Wallberg, Fredrik, Sawyer, Elinor J., Martin, Lesley-Ann, Dowsett, Mitch, Linardopoulos, Spiros, Natrajan, Rachael, Ryan, Colm J., Derksen, Patrick W.B., Jonkers, Jos, Tutt, Andrew N.J., Ashworth, Alan, Lord, Christopher J.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2018
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6296442/
https://ncbi.nlm.nih.gov/pubmed/29610289
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-17-0603
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge